GlassScriptPhysician profile
Marcus Ashton Washington
NPI 1225026479
$3,390.83
in general payments reported to CMS, 2019-2025
29 companies · $1,184 in 2025
The $1,184 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $239 · 2022: $203 · 2023: $767 · 2024: $997 · 2025: $1,184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,949.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,948.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $523.91 | 2023-2025 | |
| Abbvie INC. | $388.58 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Astrazeneca Pharmaceuticals LP | $339.98 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $292.89 | 2021-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $221.31 | 2022-2025 | Jardiance, Zepbound, Mounjaro |
| Astellas Pharma US INC | $197.79 | 2024-2025 | Veozah |
| Exact Sciences Corporation | $188.49 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $140.91 | 2022-2025 | Evenity, Prolia, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $132.40 | 2021-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $122.89 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $120.96 | 2021-2024 | Xifaxan |
| Kyowa Kirin, INC. | $83.93 | 2024-2025 | Crysvita |
| Abbott Laboratories | $74.83 | 2023-2025 | Freestyle Libre 3, Eterna |
| Bayer Healthcare Pharmaceuticals INC. | $74.70 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $57.51 | 2025 | Voquezna |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $57.19 | 2023-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $45.37 | 2025 | Trelegy Ellipta |
| Inari Medical, INC. | $43.90 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Amarin Pharma, INC. | $43.38 | 2021 | |
| Daiichi Sankyo INC. | $40.37 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $32.58 | 2022 | |
| Verona Pharma, INC. | $29.63 | 2025 | Ohtuvayre |
| Medtronic, INC. | $28.77 | 2023 | Intellis Adaptivestim |
| Esperion Therapeutics, INC. | $25.46 | 2021 | |
| Stryker Corporation | $22.82 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Edwards Lifesciences Corporation | $17.70 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Merck Sharp & Dohme LLC | $15.47 | 2024 | Capvaxive, Gardasil 9, Vaxneuvance |
| Dynavax Technologies Corporation | $14.43 | 2023 | Heplisav-B |
| Janssen Pharmaceuticals, INC | $12.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcus Washington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.